Enoximone (INN, trade name Perfan) is an imidazole phosphodiesterase inhibitor. It is used in the treatment of congestive heart failure and is selective for phosphodiesterase 3. [1]

2007年10月20日 · Enoximone is a selective phosphodiesterase inhibitor with vasodilating and positive inotropic activity that does not cause changes in myocardial oxygen consumption. It is …

Enoximone is a phosphodiesterase type-3 inhibitor that exerts most effect on the myocardium; it has positive inotropic properties and vasodilator activity. Indications and dose For enoximone

Enoximone is an imidazole derivative with selective PDE III inhibition. It is useful for the short-term support of cardiac output in patients with chronic heart failure, in whom elevated …

Enoximone 是一种正性肌力血管舒张剂，也是一种选择性的，具有口服活性的磷酸二酯酶 III (PDE3) 抑制剂，IC50 为 5.9 μM。 Enoximone 通过抑制 cGMP 抑制的 PDE 来诱导血管舒张并 …

The primary objective is a reduction in auto-positive end-expiratory pressure (PEEP) after enoximone compared to baseline. A dose-titration will test for dose dependency. Secondary …

Enoximone is an inotropic vasodilating agent and a selective and orally active phosphodiesterase III inhibitor with an IC 50 of 5.9 μM. Enoximone induces vasodilatation and increases …

本品在肝、脾、肾及白血病细胞中逐渐代谢转化成阿糖胞苷，后者抑制DNA合成而显示抗肿瘤作用。 英文名称：Enoximone (MDL-17043,Fenoximone) 、 氢甲苯咪酮，甲硫咪唑酮，腈甲咪酮. …

2012年10月31日 · Enoximone is an imidazolone derivative currently undergoing trials in patients with congestive heart failure refractory to conventional therapy. It is a phosphodiesterase …

Enoximone is an imidazolone derivative currently undergoing trials in patients with congestive heart failure refractory to conventional therapy. It is a phosphodiesterase inhibitor with both …